Literature DB >> 19855943

[Orogenital and conjunctival involvement in hereditary and autoimmune blistering diseases].

M Laimer1, C M Lanschützer, M Emberger, E Nischler, J Stoiber, H Hintner.   

Abstract

Chronic involvement of orogenital and conjunctival mucosa in the course of either genetically based (epidermolysis bullosa hereditaria) or auto-immunologically mediated (as for example pemphigus vulgaris, mucous membrane pemphigoid or epidermolysis bullosa acquisita) blistering diseases can cause significant morbidity. To provide accurate care, recognition of clinical, pathogenic and diagnostic features as well as awareness of recent advances in the development of new therapeutic modalities are mandatory and thus will be discussed in this review.

Entities:  

Mesh：

Year:  2009        PMID： 19855943     DOI： 10.1007/s00105-009-1804-3

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


  16 in total

Review 1.  Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome.

Authors:  John R Stanley; Masayuki Amagai
Journal:  N Engl J Med       Date:  2006-10-26       Impact factor: 91.245

2.  Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida.

Authors:  C Bédane; J R McMillan; S D Balding; P Bernard; C Prost; J M Bonnetblanc; L A Diaz; R A Eady; G J Giudice
Journal:  J Invest Dermatol       Date:  1997-06       Impact factor: 8.551

3.  Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing.

Authors:  David T Woodley; Jennifer Remington; Yi Huang; Yingping Hou; Wei Li; Douglas R Keene; Mei Chen
Journal:  Mol Ther       Date:  2007-01-23       Impact factor: 11.454

4.  Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa.

Authors:  Tracy Wong; Luke Gammon; Lu Liu; Jemima E Mellerio; Patricia J C Dopping-Hepenstal; John Pacy; George Elia; Rosemary Jeffery; Irene M Leigh; Harshad Navsaria; John A McGrath
Journal:  J Invest Dermatol       Date:  2008-04-03       Impact factor: 8.551

5.  Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases.

Authors:  Michael Hertl; Detlef Zillikens; Luca Borradori; Leena Bruckner-Tuderman; Harald Burckhard; Rüdiger Eming; Andreas Engert; Matthias Goebeler; Silke Hofmann; Nicolas Hunzelmann; Franz Karlhofer; Ocko Kautz; Undine Lippert; Andrea Niedermeier; Martin Nitschke; Martin Pfütze; Marcel Reiser; Christian Rose; Enno Schmidt; Iakov Shimanovich; Michael Sticherling; Sonja Wolff-Franke
Journal:  J Dtsch Dermatol Ges       Date:  2008-01-14       Impact factor: 5.584

6.  Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo.

Authors:  David T Woodley; Douglas R Keene; Tom Atha; Yi Huang; Ramin Ram; Noriyuki Kasahara; Mei Chen
Journal:  Mol Ther       Date:  2004-08       Impact factor: 11.454

7.  Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa.

Authors:  David T Woodley; Douglas R Keene; Tom Atha; Yi Huang; Kathi Lipman; Wei Li; Mei Chen
Journal:  Nat Med       Date:  2004-06-13       Impact factor: 53.440

Review 8.  Rituximab in treatment-resistant autoimmune blistering skin disorders.

Authors:  Enno Schmidt; Eva-Bettina Bröcker; Matthias Goebeler
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

9.  Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone.

Authors:  David T Woodley; Gerald G Krueger; Cynthia M Jorgensen; Janet A Fairley; Tom Atha; Yi Huang; Lawrence Chan; Douglas R Keene; Mei Chen
Journal:  J Invest Dermatol       Date:  2003-11       Impact factor: 8.551

10.  Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells.

Authors:  Fulvio Mavilio; Graziella Pellegrini; Stefano Ferrari; Francesca Di Nunzio; Enzo Di Iorio; Alessandra Recchia; Giulietta Maruggi; Giuliana Ferrari; Elena Provasi; Chiara Bonini; Sergio Capurro; Andrea Conti; Cristina Magnoni; Alberto Giannetti; Michele De Luca
Journal:  Nat Med       Date:  2006-11-19       Impact factor: 53.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.